Publications by authors named "K B Yago"
Background Aims: Methotrexate (MTX) is used as standard graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation. However, the optimal dosing regimen among the various MTX regimens available remains unclear.
Methods: We used the registration data of Kyoto Stem Cell Transplantation Group to compare six MTX dosing protocols in a multicenter retrospective analysis of 816 cases of unrelated bone marrow or peripheral blood stem cell transplantation.
Article Synopsis
- Haploidentical donor transplantation using posttransplant cyclophosphamide (PTCy) and cord blood transplantation (CBT) are effective alternatives when matched donor options are not available for patients with blood cancers.
- The study analyzed 914 patients and found that mild acute graft-versus-host disease (GVHD) improved overall survival after PTCy-haplo and CBT but did not have the same benefit for matched donor transplants.
- Additionally, while limited chronic GVHD positively impacted outcomes after CBT and matched donor transplants, it did not show the same effect after PTCy-haplo, highlighting that the impact of GVHD varies depending on the type of transplant.
Article Synopsis
- - The study focused on improving outcomes of allogeneic hematopoietic stem cell transplantation by using a personalized busulfan (BU) dosing strategy, comparing it to a fixed-dose regimen.
- - Results showed that using a combination of test doses and therapeutic drug monitoring improved BU exposure control, particularly benefiting patients on fludarabine (FLU) regimens, with lower relapse rates and better overall survival compared to fixed doses.
- - The trial demonstrated an impressive 85.5% progression-free survival rate at 100 days for the PK-guided group, suggesting that tailored dosing may enhance treatment effectiveness for hematological malignancies.
Article Synopsis
- Cord blood transplantation (CBT) is a promising treatment for patients with blood cancers and can tolerate mismatches in HLA (human leukocyte antigen), which are vital for transplant compatibility.
- A study of 492 patients found that higher levels of HLA DRB1 mismatches were linked to better outcomes, such as lower relapse rates and improved disease-free survival, particularly for those in complete or partial remission.
- In contrast, while higher HLA class I mismatches were associated with increased risk of nonrelapse mortality for advanced stage patients, they did not show an advantage for preventing relapse, indicating the complexity of HLA mismatches' effects on transplant success.
Viral infection is one of the lethal adverse events after cord blood transplantation (CBT). Human leukocyte antigen (HLA) and killer immunoglobulin-like receptor (KIR) ligand divergences can increase the risk of viral infection due to conflicting interactions between virus-infected cells and immune cells. However, the relationship between these disparities and the frequency of viral infection after CBT remains to be evaluated.
View Article and Find Full Text PDF